Search research articles
Contact Us
Filters
Showing results (31-40 of 68) with videos related to
Page
of 7
Sort By:
Cancer Immunology, Immunotherapy : CII
|
January 10, 2020
Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer
Morten Orebo Holmström, Sabrina Cordua, Vibe Skov, et al.
Hemasphere
|
December 7, 2020
Digital PCR for <i>BCR-ABL1</i> Quantification in CML: Current Applications in Clinical Practice
Camille C B Kockerols, Peter J M Valk, Mark-David Levin, et al.
Ugeskrift for Laeger
|
October 13, 2006
[New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene]
Thomas Stauffer Larsen, Niels Pallisgaard, Jacob Haaber Christensen, et al.
Ugeskrift for Laeger
|
October 13, 2006
[New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation]
Thomas Stauffer Larsen, Niels Pallisgaard, Jacob Haaber Christensen, et al.
British Journal of Cancer
|
April 20, 2022
Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
Louise B Callesen, Julian Hamfjord, Anders K Boysen, et al.
Ugeskrift for Laeger
|
November 6, 2009
[Eosinophilia--pathogenesis, classification and therapy]
Christen Lykkegaard Andersen, Hanne Vestergaard, Peter Nørgaard, et al.
Translational Oncology
|
August 8, 2018
Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing
Christina Demuth, Karen-Lise Garm Spindler, Julia S Johansen, et al.
Clinical Hematology International
|
October 1, 2021
Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
Kristian T Andersen, Maja Hinge, Agoston Gyula Szabo, et al.
BMC Gastroenterology
|
April 7, 2022
Perioperative changes in cell-free DNA for patients undergoing surgery for colon cancer
Andreas W Rosen, Mikail Gögenur, Isabella W Paulsen, et al.
Acta Oncologica (Stockholm, Sweden)
|
March 22, 2013
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma
Karen-Lise G Spindler, Morten M Sorensen, Niels Pallisgaard, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 68) with videos related to
Sort By:
Page
of 7
Cancer Immunology, Immunotherapy : CII
|
January 10, 2020
Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer
Morten Orebo Holmström, Sabrina Cordua, Vibe Skov, et al.
Hemasphere
|
December 7, 2020
Digital PCR for <i>BCR-ABL1</i> Quantification in CML: Current Applications in Clinical Practice
Camille C B Kockerols, Peter J M Valk, Mark-David Levin, et al.
Ugeskrift for Laeger
|
October 13, 2006
[New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene]
Thomas Stauffer Larsen, Niels Pallisgaard, Jacob Haaber Christensen, et al.
Ugeskrift for Laeger
|
October 13, 2006
[New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation]
Thomas Stauffer Larsen, Niels Pallisgaard, Jacob Haaber Christensen, et al.
British Journal of Cancer
|
April 20, 2022
Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
Louise B Callesen, Julian Hamfjord, Anders K Boysen, et al.
Ugeskrift for Laeger
|
November 6, 2009
[Eosinophilia--pathogenesis, classification and therapy]
Christen Lykkegaard Andersen, Hanne Vestergaard, Peter Nørgaard, et al.
Translational Oncology
|
August 8, 2018
Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing
Christina Demuth, Karen-Lise Garm Spindler, Julia S Johansen, et al.
Clinical Hematology International
|
October 1, 2021
Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
Kristian T Andersen, Maja Hinge, Agoston Gyula Szabo, et al.
BMC Gastroenterology
|
April 7, 2022
Perioperative changes in cell-free DNA for patients undergoing surgery for colon cancer
Andreas W Rosen, Mikail Gögenur, Isabella W Paulsen, et al.
Acta Oncologica (Stockholm, Sweden)
|
March 22, 2013
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma
Karen-Lise G Spindler, Morten M Sorensen, Niels Pallisgaard, et al.
Page
of 7